CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral Anticoagulants SR-B1 Drives Endothelial Cell LDL Transcytosis via DOCK4 to Promote Atherosclerosis Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease : A Special Report From the American Heart Association and American College of Cardiology Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial Sox17 Controls Emergence and Remodeling of Nestin-Expressing Coronary Vessels

Original Research

JOURNAL:CBSMD Article Link

无复流现象

CBSMD

Pre-reading

2001年,Eeckhout和Kern将无复流现象(No-Flow Phenomenon)定义为冠状动脉循环中某一特定血管节段虽心肌灌注不足,但无机械性血管阻塞(mechanical vessel obstruction)冠状动脉造影证据。经皮冠状动脉介入治疗支架置入后在明确没有可见残余狭窄后,术者将首要关注冠状动脉血流,若发生无复流现象,或将进一步影响预后及左心室重构,增加不良心脏事件的风险。因此熟知可预防无复流现象的策略、药物(冠状动脉内注射腺苷intracoronary adenosine, 硝普钠nitropusside)和非药物(低体温法induced hypothermia)等干预法对提高介入质量、改善患者预后的重要性不言而喻。